TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Allurion Technologies (NYSE:ALUR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Profitability
This table compares TriSalus Life Sciences and Allurion Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -60.85% | N/A | -69.91% |
| Allurion Technologies | -199.96% | N/A | -77.13% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for TriSalus Life Sciences and Allurion Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 1 | 1 | 2 | 0 | 2.25 |
| Allurion Technologies | 1 | 1 | 1 | 0 | 2.00 |
Institutional & Insider Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 8.1% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares TriSalus Life Sciences and Allurion Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $45.15 million | 5.13 | -$39.23 million | ($1.41) | -2.67 |
| Allurion Technologies | $17.21 million | 0.58 | -$7.20 million | ($2.03) | -0.33 |
Allurion Technologies has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
TriSalus Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.
Summary
TriSalus Life Sciences beats Allurion Technologies on 9 of the 13 factors compared between the two stocks.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
